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Sleep Apnea, the Risk of Developing Heart Failure, and Potential
Beneﬁts of Continuous Positive Airway Pressure (CPAP) Therapy
Anders Holt, MB; Jenny Bjerre, MD; Bochra Zareini, MD; Henning Koch, MD; Philip Tønnesen, MD, DMSC; Gunnar H. Gislason, MD, PhD;
Olav W. Nielsen, MD, PhD, DMSC; Morten Schou, MD, PhD; Morten Lamberts, MD, PhD
Background-—Whether there is an association between sleep apnea (SA) and the risk of developing heart failure (HF) is unclear.
Furthermore, it has never been established whether continuous positive airway pressure (CPAP) therapy can prevent development
of HF. We aimed to investigate SA patients’ risk of developing HF and the association of CPAP therapy.
Methods and Results-—Using nationwide databases, the entire Danish population was followed from 2000 until 2012. patients
with SA receiving and not receiving CPAP therapy were identiﬁed and compared with the background population. The primary end
point was ﬁrst-time hospital contact for HF and adjusted incidence rate ratios of HF were calculated using Poisson regression
models. Among 4.9 million individuals included, 40 485 developed SA during the study period (median age: 53.4 years, 78.5%
men) of whom 45.2% received CPAP therapy. Crude rates of HF were increased in all patients with SA relative to the background
population. In the adjusted model, the incidence rate ratios of HF were increased in the untreated SA patients of all ages,
compared with the background population. Comparing the CPAP-treated patients with SA with the untreated patients with SA
showed signiﬁcantly lower incidence rate ratios of HF among older patients.
Conclusions-—In this nationwide cohort study, SA not treated with CPAP was associated with an increased risk of HF in patients of
all ages. Use of CPAP therapy was associated with a lower risk of incident HF in patients >60 years of age, suggesting a protective
effect of CPAP therapy in the elderly. ( J Am Heart Assoc. 2018;7:e008684. DOI: 10.1161/JAHA.118.008684.)
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S leep apnea (SA) is associated with increased risk ofcardiovascular events, worsening of heart failure
(HF), metabolic disturbances, and overall a reduced quality
of life.1–4 One study even found an increased risk of incident
HF among men with obstructive sleep apnea (OSA).5 Contin-
uous positive airway pressure (CPAP) therapy is a docu-
mented treatment for SA because of symptom relief, but it
may also reduce endothelial damage and improve blood
pressure, glucose tolerance, and cardiac function in patients
with HF.6–10 However, a direct beneﬁcial effect of CPAP
therapy on cardiovascular outcomes has never been estab-
lished in a controlled setting.11,12 However, adaptive ser-
voventilation has recently been shown to in fact increase
mortality in a randomized setting of patients with HF with
reduced ejection fraction and central SA,13 causing some
concern about the use of noninvasive ventilation in these
patients. Although the latter study investigated central SA
patients with established chronic HF with reduced ejection
fraction, it calls for further studies because the interplay
between SA, cardiac disease, and pressure therapies is not
fully understood.14 It may be speculated that in patients with
OSA, CPAP therapy could prevent development of HF because
of its positive effect on blood pressure and metabolic
function.8–10 We therefore aimed to investigate the relation-
ship between SA, incident HF, and the association of CPAP
therapy in an unselected real-life population.
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Methods
The data, analytic methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure. The raw data
are available through Denmark’s Statistics on request.
Databases
All Danish inhabitants are provided with a unique personal
identiﬁcation number at birth or immigration that enables
cross-linkage of information from nationwide databases.
The Danish National Patient Registry holds information on
hospital contacts, including diagnoses and procedural codes.
Contacts are coded per the International Classiﬁcation of
Diseases (ICD)—the 8th revision before 1994 (ICD-8) and the
10th revision thereafter (ICD-10).
The National Prescription Registry holds information on
date and amount of all redeemed prescriptions coded per the
Anatomical Therapeutic Chemical classiﬁcation system.
All used Anatomical Therapeutic Chemical and ICD codes
are shown in Table S1. The Danish Civil Registration system
provides data on date of birth, sex, immigration/emigration
history, and vital status.
Study Population and Baseline Characteristics
All individuals (the entire Danish population) were included on
January 1, 2000 and followed until December 31, 2012.
Individuals immigrating within the study period were included
at date of immigration. Exclusion criteria included age <18 or
>100 years, and a prior diagnosis of SA or HF (Figure 1). The
following characteristics were deﬁned binarily as present or
not present at the date of inclusion: myocardial infarction
(MI), ischemic stroke, atrial ﬁbrillation, peripheral arterial
disease, chronic kidney disease, liver disease, chronic
obstructive pulmonary disease, and cancer (excluding non-
melanoma skin cancer). These diagnoses have been previ-
ously validated with high positive predictive values.15
Medication was deﬁned as a prescription that was ﬁlled up
to 180 days before date of inclusion of the following
medicines: statins, b-blockers, loop diuretics, antihyperten-
sive drugs, antiplatelet agents, and NSAIDs.
In order to include patients being treated for hypertension
and diabetes mellitus outside of hospitals (eg, in general
practice), we deﬁned hypertension as a combination treat-
ment with at least 2 antihypertensive drugs and diabetes
mellitus as treatment with a glucose-lowering drug, as has
been done previously.16
Deﬁnitions of SA and CPAP Therapy
We identiﬁed all patients in the study population registered
with a diagnosis of SA. The SA diagnosis in the Danish
Figure 1. Study population, inclusions and exclusions. HF
indicates heart failure; SA, sleep apnea.
Clinical Perspective
What Is New?
• Among patients with sleep apnea, there is an increased risk
of the development of heart failure across all ages.
• Among patients with sleep apnea, aged ≥60 years, the use
of continuous positive airway pressure (versus no treat-
ment) decreases the risk of the development of new-onset
heart failure.
What Are the Clinical Implications?
• Clinicians should acknowledge growing evidence of the
adverse cardiovascular effects of sleep apnea, and in
particular, its association with heart failure.
• Early diagnosis and treatment of sleep apnea may poten-
tially reduce associated morbidity and mortality, in addition
to increasing the quality of life.
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National Patient Registry has previously been validated with a
positive predictive value of 82%.1
At the date of SA diagnosis, patients changed status from
the background population to patients with SA. Procedural
codes involving CPAP therapy were used to identify patients
with SA who received CPAP therapy. To ensure adherence to
therapy, 2 successive procedural codes were required: the
ﬁrst code representing distribution of CPAP equipment and
second code indicating redistribution and probable continu-
ous use after a tryout period. Thus, the second procedural
date deﬁned initiation of CPAP therapy.
Outcome
HF was deﬁned as a ﬁrst-time primary or secondary diagnosis
registered at hospitalization or at an outpatient visit. The
following diagnoses were included: hypertensive HF, car-
diomyopathy, cardiac insufﬁciency, left-sided HF, lung edema,
and unspeciﬁed HF (Table S1). Two separate studies have
validated the HF diagnosis in the Danish National Patient
Registry and found positive predictive values of 84% (77.9%
for ﬁrst-time HF) and 81%, respectively.17,18
Statistical Analysis
Both SA diagnosis and CPAP therapy were treated as time-
dependent values, meaning that the subjects contributed time
at-risk in the background population until the date of SA
diagnosis. Individuals were followed until study end, emigra-
tion, death, or event of interest, whichever came ﬁrst. A
statistical interaction between age and the use of CPAP
therapy was found (P<0.0001); thus, the patients were
stratiﬁed into 2 age groups: 18 to 60 and >60 years of age.
This age stratiﬁcation was applied to all analyses.
Multivariable Poisson regression models were ﬁtted to
estimate incidence rate ratios (IRRs) of incident HF between
3 groups; (1) the background population (reference),
(2) untreated patients with SA, and (3) patients with CPAP-
treated SA. We calculated crude rates as events per 1000
person-years at risk with respect to age and follow-up time.
Furthermore, we estimated IRRs using 2 different models:
Model 1: Adjusted for age, sex, calendar year, and comor-
bidities present at the date of inclusion (including MI,
ischemic stroke, hypertension, atrial ﬁbrillation, peripheral
arterial disease, chronic obstructive pulmonary disease,
cancer, diabetes mellitus, and the use of NSAIDs), and Model
2: Fully adjusted model with all covariates mentioned in Model
1 incorporated as time-dependent variables (eg, if subjects
developed hypertension 5 years into the study period, they
contributed 5 years at-risk time to the model without
hypertension and the rest of the study period the subjects
were considered to have hypertension).
The latter model was also used to estimate the association
of CPAP therapy. For this analysis, the reference group was
SA patients not receiving CPAP therapy; thus, we compared
the use of CPAP therapy versus no CPAP therapy among
patients with SA only.
Interactions between use of CPAP therapy and predeﬁned
clinically relevant comorbidities were systematically checked
and were found to be statistically signiﬁcant for MI and
hypertension; thus, we performed subgroup analyses of these
groups (Table 1). We found no effect-modiﬁcation for sex.
Model assumptions, including proportional hazards, inde-
pendent observations, goodness-of-ﬁt v2 test, and homo-
geneity of variance, were found to be valid.
Sensitivity Analyses
Two sensitivity analyses were performed. First, we altered the
primary outcome deﬁnition to include both a HF diagnosis and
a ﬁlled prescription of any dose of loop-diuretics between
45 days before to 45 days after the HF diagnosis, as has
Table 1. Results From Subgroup Analyses
Subgroup Age (y)
SA Patients Not Receiving CPAP Therapy SA Patients Receiving CPAP Therapy
Total No. of Events IRR (95% CI) Total No. of Events IRR (95% CI)
Patients with MI excluded 18–60 184 1.41 (1.22–1.64) 78 1.28 (1.01–1.61)
>60 450 1.49 (1.35–1.64) 190 1.27 (1.10–1.48)
Only patients with MI included 18–60 42 0.58 (0.42–0.81) 25 0.87 (0.58–1.29)
>60 170 1.13 (0.97–1.32) 75 0.89 (0.70–1.12)
Patients with HT excluded 18–60 115 1.67 (1.38–2.02) 51 2.06 (1.57–2.72)
>60 207 1.53 (1.33–1.75) 79 1.24 (0.99–1.56)
Only patients with HT included 18–60 111 0.88 (0.73–1.08) 52 0.75 (0.56–1.00)
>60 413 1.29 (1.17–1.43) 186 1.04 (0.90–1.21)
All analyses were performed using the fully adjusted time-dependent Model 2 with background population as reference. CI indicates conﬁdence intervals; CPAP, continuous positive airway
pressure; HT, hypertension; IRR, incidence rate ratio; MI, myocardial infarction; SA, sleep apnea.
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been done previously.16,18 Loop-diuretics are considered ﬁrst-
line symptomatic treatment; thus, this restricted HF outcome
was to only include potential symptomatic patients with HF.
In the second analysis, we excluded all patients with a
ﬁlled prescription of any dose of loop-diuretics up to 180 days
before the date of inclusion, thereby excluding patients
possibly in treatment for unregistered HF.
Both analyses were performed using the adjusted time-
dependent Model 2 (Table 2).
Ethical Considerations
Statistics Denmark provided access to the databases men-
tioned earlier, and permission to use data from the registries
was granted by the Danish Data Protection Agency (Ref. j.no.
2007-58-0015/local j.nr. GEH-2014-015, I-suite no. 02733).
In Denmark, registry-based studies do not require ethical
approval.
Results
We identiﬁed 4.9 million Danish adults who were followed
up to 13 years (Figure 1). During the study period, 40 485
patients (0.8%) received a ﬁrst-time diagnosis of SA (86%
unspeciﬁed SA, 13% obstructive SA, and <1% other forms
of SA). SA patients were followed for a median time of
3.8 years (interquartile range [IQR] 1.8–6.4 years) and
CPAP therapy was initiated in 45.2% with a median time
to CPAP therapy initiation of 99 days (IQR 35–405 days).
Patients with SA receiving CPAP therapy were older
(median age of 55.7 years [IQR 47.3–63.2]) compared with
the background population (43.1 years, [IQR 30.2–57.9]) as
well as with the patients with SA not receiving CPAP
therapy (52.4 years, [IQR 43.2–60.8]). Patients with SA
receiving CPAP therapy had a higher burden of comorbidi-
ties and concomitant pharmacological therapy compared
with both of the other groups (Table 3).
Risk of Incident HF and Association of CPAP
Therapy
Crude rates per 1000 person-years at risk were calculated for
the background population and SA patients stratiﬁed by CPAP
therapy (Figure 2 and Table 4). In the background population
and in patients with SA not receiving CPAP therapy, IRRs
(from the adjusted time-dependent Model 2) were increased
in both age groups, but only signiﬁcantly and most pro-
nounced among the patients >60 years of age. We did not
ﬁnd a statistically signiﬁcant difference in IRRs between the
CPAP-treated patients with SA and the background population
(Table 4).
In patients who had SA and who were >60 years of age,
CPAP therapy was associated with a signiﬁcantly lower IRR of
HF compared with patients with SA of the same age who did
not receive CPAP therapy. We found the same nonsigniﬁcant
tendency in patients with SA between 18 and 60 years of age
(Table 4).
Subgroup and Sensitivity Analyses
The subgroup analyses were performed to evaluate effect-
modiﬁcation from MI and hypertension on the risk of
developing HF. The results from the subgroup analyses were
comparable to the main analysis (Table 1). Likewise, both
sensitivity analyses (restriction of HF diagnosis and exclusion
of potentially nonregistered HF patients) were comparable to
the main results or nonsigniﬁcant because there were few
events (Table 2).
Discussion
This study has 2 main ﬁndings. First, SA not treated with
CPAP was associated with an increased risk of HF in patients
of all ages, but only signiﬁcantly in patients >60 years of age.
Second, use of CPAP therapy was associated with a lower risk
Table 2. Results From Sensitivity Analyses
Sensitivity Analyses Age (y)
Background Population SA Patients Not Receiving CPAP Therapy SA Patients Receiving CPAP Therapy
Total No. of Events IRR Total No. of Events IRR (95% CI) Total No. of Events IRR (95% CI)
(1) 18–60 2520 Ref 21 0.81 (0.51–1.29) 15 1.43 (0.84–2.43)
>60 38 889 Ref 157 1.94 (1.65–2.28) 64 1.59 (1.22–2.06)
(2) 18–60 21 160 Ref 213 1.17 (1.01–1.34) 95 1.06 (0.86–1.31)
>60 130 922 Ref 532 1.37 (1.25–1.49) 222 1.02 (0.89–1.17)
(1) Outcome redeﬁned as heart failed diagnosis+ﬁlled loop-prescription. (2) Patients with a ﬁlled loop-prescription before study start were excluded. All analyses were performed using the
fully adjusted time-dependent Model 2 with background population as reference. CI indicates conﬁdence intervals; CPAP, continuous positive airway pressure; IRR, incidence rate ratio; SA,
sleep apnea.
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of incident HF in patients >60 years of age compared with
patients with SA not receiving CPAP therapy.
Risk of HF
There are different theories concerning the role of SA in the
development of HF: First, obstructive SA generates a negative
intrathoracic pressure, increasing both cardiac preload and
afterload. Second, consecutive intermittent hypoxic periods
increase oxidative stress and inﬂammation markers, which in
turn can damage the endothelial walls. Third, disrupted sleep
increases sympathetic nervous activity, leading to an increase
in blood pressure and heart rate, which demands cardiac
activity at a time when the heart should be regenerating.2,19,20
In addition, several studies have shown that SA is associated
with hypertension, coronary artery disease, arrhythmias,
obesity, diabetes mellitus, and metabolic disturbances, all
known to increase the risk of HF.2,3,21,22 Hence, we applied
many of these comorbidities in our regression models,
including continuous assessment of their presence. Use of
NSAIDs has been associated with increased risk of HF and
was therefore included in the model as well.23,24 Although
lower estimates were found (Model 2 compared with Model 1,
Table 4), the IRRs were still signiﬁcantly increased; thus, SA
seems to be an independent risk factor for developing HF.
Nevertheless, the pathophysiology of HF and the causal
pathway and interplay between SA and HF are heterogeneous
and possibly other mechanisms associated with SA could be
involved.
The relationship between SA and HF has been investigated
in several studies. In a prospective study, nearly 4500
patients with OSA were followed and no signiﬁcant associ-
ation between the severity of OSA and HF was found.5
However, the study was relatively small and the authors did
Table 3. Characteristics of the Study Population
Total Population SA Patients Not Receiving CPAP Therapy SA Patients Receiving CPAP Therapy
Total, n 4 870 975 22 168 18 317
Men, n (%) 2 430 969 (49.9) 17 114 (77.2) 14 654 (80.0)
Age (y), median (IQR) 43.1 (30.2–57.9) 52.4 (43.2–60.8) 55.7 (47.3–63.2)
Comorbidities, n (%)
Myocardial infarction 68 802 (1.4) 792 (3.6) 760 (4.2)
Ischemic stroke 85 745 (1.8) 1051 (4.7) 944 (5.2)
Hypertension 328 510 (6.7) 5690 (25.7) 6565 (35.8)
Atrial fibrillation 36 143 (0.7) 803 (3.6) 874 (4.8)
Peripheral arterial disease 33 651 (0.7) 341 (1.5) 303 (1.7)
Chronic kidney disease 21 749 (0.4) 469 (2.1) 450 (2.5)
Liver disease 34 530 (0.7) 405 (1.8) 349 (1.9)
COPD 58 943 (1.2) 1042 (4.7) 911 (5.0)
Cancer* 108 911 (2.2) 960 (4.3) 929 (5.1)
Diabetes mellitus 320 466 (6.6) 3733 (16.8) 3518 (19.2)
Medication n (%)
Statins 60 458 (1.2) 782 (3.5) 796 (4.3)
Loop diuretics 104 934 (2.2) 564 (2.5) 500 (2.7)
RAS inhibitors 165 962 (3.4) 1554 (7.0) 1491 (8.1)
b-Blockers 159 371 (3.3) 1098 (5.0) 1113 (6.1)
Oral anticoagulants 17 253 (0.4) 127 (0.6) 128 (0.7)
Aspirins 171 847 (3.5) 877 (4.0) 811 (4.4)
NSAIDs 428 388 (8.8) 3730 (16.8) 3499 (19.1)
Calcium antagonists 158 328 (3.3) 1213 (5.5) 1167 (6.4)
Thiazides 168 014 (3.4) 1035 (4.7) 2227 (12.2)
Baseline characteristics at the date of inclusion for the total population, at the time of SA diagnosis (only the untreated patients), and at the time of initiation of CPAP therapy. COPD
indicates chronic obstructive pulmonary disease; CPAP, continuous positive airway pressure; IQR, interquartile range; RAS, renin-angiotensin system; SA, sleep apnea.
*All cancers, excluding nonmelanoma skin cancers.
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not report any age-speciﬁc relation. Conversely, a matched
study showed an increased risk of fatal and nonfatal
cardiovascular complications in patients with severe OSA
compared with healthy matched controls (matched on age
and body mass index).25 A cross-sectional study of elderly
patients showed the same association between severe SA and
cardiovascular disease (deﬁned by 1 of the following: MI,
angina, coronary revascularization procedure, HF or stroke),
though the cross-sectional design could not tell whether the
patients developed SA or HF ﬁrst.26 Our study, with up to
13 years of follow-up on >40 000 patients with SA and
consecutive adjustment for other cardiovascular risk factors,
is in line with the studies showing an association between SA
and HF.
Effect of CPAP Therapy
Because it provides symptom relief, CPAP therapy is ﬁrst-line
therapy for SA, but could theoretically also reduce the
negative cardiovascular impacts of SA as it has been found to
improve glucose tolerance, reduce endothelial damage, lower
blood pressure, and improve cardiac function.6–10 Conse-
quently, one could hypothesize that CPAP therapy protects
patients from developing cardiovascular disease such as HF.
The effect of CPAP therapy on cardiovascular disease has
been investigated to some extent, but with conﬂicting results.
SAVE (Results from the Survival and Ventricular Enlargement)
trial found no signiﬁcant difference in cardiovascular events
between a “usual-care group” and a “CPAP therapy+usual-
care group.”11 In line with this, a randomized controlled study
of 725 patients with OSA was unable to show a signiﬁcant
effect of CPAP therapy on the development of HF.12 Opposed
to these neutral ﬁndings, the previously mentioned matched
study by Marin et al found a potential beneﬁcial effect of
CPAP therapy on cardiovascular complications in patients
with severe OSA.25 Likewise, our study showed in, to our
knowledge, the largest cohort of SA patients to date that
CPAP therapy was associated with a lower risk of developing
HF in patients >60 years of age. A potential difference in
adherence to medical treatment in general could be an
explanation for the observed difference between patients with
SA who did and did not receive CPAP therapy, assuming that a
patient who accepts CPAP therapy might also be more
adherent to pharmacotherapy, for example. In our cohort, the
CPAP-treated patients with SA received more medication on
the date of inclusion compared with the patients with SA not
in CPAP therapy. However, these patients also had a higher
comorbidity burden (included in the model), which could
explain the increase in medication (Table 3). However, these
differences cannot be statistically conﬁrmed because of the
time-dependent study design and absence of independent
observations, though the observed differences seem substan-
tial. Adherence to medical treatment in patients with SA has
been investigated in a cohort of 2158 patients with severe
OSA; in this study the authors found high medication
adherence among all patients and, remarkably, no difference
in medication adherence between patients adherent and
nonadherent to CPAP therapy.27 This supports our ﬁndings of
Figure 2. Crude incidence rates of HF stratiﬁed by 10-year age intervals and in 3 groups: background
population, SA patients not receiving CPAP therapy, and SA patients receiving CPAP therapy. CPAP
indicates continuous positive airway pressure; HF, heart failure; SA, sleep apnea.
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CPAP therapy possibly playing an active role in reducing the
risk of developing HF in SA patients. Concerningly, recently
published data from the SERVE-HF (Servoventilation in
Patients with Heart Failure) trial showed that adaptive
servoventilation increased overall mortality risk in 1325
patients with chronic HF with reduced ejection fraction with
predominantly central SA.13 As a result, adaptive servoven-
tilation is not recommended in patients with HF and
predominantly central SA.28 However, the safety concern
that arose from this study should not be applied to patients
with SA without HF receiving CPAP therapy, since adaptive
servoventilation and CPAP therapy are completely different
modes of applying positive airway pressure,29,30 and the
increased mortality was only demonstrated in patients already
diagnosed with HF with reduced ejection fraction.13 Interest-
ingly, the US preventive service task force recently recom-
mended not to screen for OSA because of insufﬁcient
evidence on beneﬁts and harms of a screening program
and, especially, because of the lack of evidence concerning
the potential beneﬁcial effect of CPAP therapy on hard
outcomes.31 Our study adds important data to the discussion
concerning the cardiovascular risk of SA as well as the
potential favorable effect of CPAP therapy. Although our study
was observational by design and only hypothesis-generating,
focus on interplay between HF and SA, including type of SA
therapy, in future studies is important.
Strengths and Limitations
Inclusion of a large, unselected, and nationwide cohort of
patients with SA independent of age, sex, socioeconomic
status, access to health services, and ethnicity are the major
strength of this study. Main limitations are the observational
study design, the use of administrative databases for all
diagnoses, and the inability to eliminate the possibility of
unmeasured confounders.
We did not have information on body mass index or
smoking status, which could both be relevant confounders
and overrepresented in the patients with SA. However, we had
information on the mediators between smoking/overweight
and HF (eg, arterial disease, diabetes mellitus, chronic
obstructive pulmonary disease, and MI). A propensity-
matched analysis could have strengthened our results, but it
was not possible because of our time-dependent study
design.
We lacked information on the severity of SA, and 86% of
the diagnoses were unspeciﬁed. Likewise, 57% of the HF
diagnoses were nonspeciﬁc, which limited us from making any
assumptions as to the direct causal pathway between SA and
HF. Positive predictive values of SA and HF diagnoses in the
Danish National Patient Registry are high; however, sensitiv-
ities are lower, which could have led to an underestimation of
our results because of type 2 errors.1,18
No signiﬁcant association was found between use of CPAP
therapy and HF among patients who have SA and are aged
between 18 and 60 years. This could simply be explained by
lack of power because of fewer events among the younger
patients. However, another explanation could be that clinical
HF has a multifactorial pathway, with factors such as
hypertension and hyperlipidemia being less present among
the younger patients. Some studies show a potential bene-
ﬁcial effect of CPAP therapy on hypertension and lipid proﬁle,
which could explain why the association between CPAP
therapy and reduced risk of HF is less pronounced among the
younger patients.8,9 Finally, the pathophysiology of develop-
ment of SA may differ between younger and older individuals
Table 4. IRRs of HF in Patients With SA Receiving and Not Receiving CPAP Therapy
Background Population
SA Patients Not Receiving CPAP
Therapy SA Patients Receiving CPAP Therapy Association* of CPAP Therapy
Crude Rate
Per 1000
Person-Y (Total
No. of Events) IRR
Crude Rate
Per 1000
Person-Y
(Total No. of
Events) IRR (95% CI)
Crude Rate
Per 1000
Person-Y (Total
No. of Events) IRR (95% CI) IRR (95% CI)
Model 1
18–60 y age 0.60 (22 430) Reference 2.94 (226) 1.61 (1.41–1.83) 3.27 (103) 1.68 (1.38–2.04) 1.05 (0.83–1.32)
>60 y of age 9.08 (154 611) Reference 13.43 (620) 1.81 (1.67–1.96) 10.30 (265) 1.50 (1.33–1.69) 0.83 (0.73–0.96)
Model 2
18–60 y of age 0.60 (22 430) Reference 2.94 (226) 1.13 (0.99–1.30) 3.27 (103) 0.97 (0.79–1.19) 0.86 (0.67–1.10)
>60 y of age 9.08 (154 611) Reference 13.43 (620) 1.38 (1.27–1.50) 10.30 (265) 1.13 (0.99–1.28) 0.81 (0.70–0.95)
Model 1: adjusted for age, sex, calendar year, and comorbidities present at inclusion (including myocardial infarction, ischemic stroke, hypertension, atrial ﬁbrillation, peripheral arterial
disease, chronic obstructive pulmonary disease, cancer, and diabetes mellitus), and the use of NSAIDs at the time of inclusion. Model 2: fully adjusted model with all covariates mentioned in
Model 1 incorporated as time-dependent variables. CI indicates conﬁdence intervals; CPAP, continuous positive airway pressure; HF, heart failure; IRR, incidence rate ratios; SA, sleep apnea.
*Estimated by comparing the patients with SA receiving CPAP therapy to the patients with SA who did not.
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(eg, body mass index might be an important factor in older
compared with younger patients); consequently, any effect of
CPAP therapy may also differ according to age. We found
effect modiﬁcation of MI and hypertension and for comparing
with the main results, we constructed subgroups for subgroup
analyses of patients with previous MI, with previous hyper-
tension, and without 1 or the other (Table 1). The results were
all similar to the main analyses. However, subgroup (previous
MI, patients with SA not receiving CPAP therapy, and 18–
60 years of age) had a decreased IRR of HF. Possible
explanations could be small number of events (power),
healthy survivor bias because of early MI not resulting in HF
in contrast to the high risk of MI causing immediate HF in the
elderly,32 or simply a random ﬁnding.
We had no information on the reasons for initiating CPAP
therapy, nor did we know the reasons for discontinuing CPAP
therapy, which is why we required 2 consecutive procedural
codes for CPAP therapy to ensure adherence. Also, we lacked
information on the daily compliance with CPAP therapy, as we
know that use <4 hours per night only has marginal effects.
Conclusions
In this nationwide cohort study of patients with SA, SA not
treated with CPAP was associated with an increased risk of
HF in patients of all ages, but only signiﬁcantly and most
markedly in patients >60 years of age. Use of CPAP therapy
was associated with a lower risk of incident HF in patients
>60 years of age, which suggests a protective effect of CPAP
therapy in this group.
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Table S1. ICD and ATC codes. 
 Details ICD-8, ICD-10, and ATC codes used 
Study population 
Sleep Apnea 
Defined from diagnosis codes, 
excluding specific code for 
central sleep apnea 
ICD-10: G473 (G4731 excluded) 
CPAP therapy Defined from procedural codes ICD-10: BGFC32, ZZ3911-ZZ3916 
Outcome 
Heart failure 
Defined from diagnosis codes 
including heart failure, 
cardiomyopathies, hypertensive 
heart failure, and lung edema. 
ICD-10: I110, I42, I50, J819 
ICD-8: 425, 4270-1 
Comorbidity 
Ischemic stroke 
Defined from diagnosis codes 
including ischemic stroke and 
transient ischemic attack 
ICD-10: I63, I64, G458, G459 
ICD-8: 433-8 
Myocardial infarction Defined from diagnosis codes 
ICD-10: I21-22 
ICD-8: 410 
Liver disease 
Defined from diagnosis codes 
of liver cancer, chronic liver 
disease, liver surgery, cirrhosis, 
and hepatitis 
ICD-10: B15-B19, C22, D684C, 
I982B, K70-K77, DQ618A, Z944 
Diabetes mellitus 
Defined from treatment with 
glucose lowering drugs 
ATC: A10 
Hypertension 
Defined from combination 
treatment with a least two classes 
ATC: C02A, C02B, C02C, C02DA, 
C02DB, C02DD, C02DG, C02L, 
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of antihypertensive drugs 
(Adrenergic α-antagonist, non-
loop-diuretics, vasodilators, beta- 
blockers, calcium channel 
blockers, and renin-angiotensin 
system inhibitors) 
C03A, C03B, C03D, C03E, C03X, 
C07A, C07B, C07C, C07D, C07F, 
C08, C09AA, C09BA, C09BB, 
C09CA, C09DA, C09DB, C09XA02, 
C09XA52 
Chronic renal failure 
Defined from diagnosis codes of 
chronic glomerulonephritis, 
chronic tubulointestinal 
nephropathy, chronic kidney 
disease, and diabetic and 
hypertensive nephropathy. 
ICD-10: E102, E112, E132, E142, 
I120, M200, M313, M319, M321B, 
N02-N08, N11-N12, N14, N18-N19, 
N26, N158-N160, N162-N164, N168, 
Q612-Q613, Q615, Q619 
ICD-8: 403, 404, 580-4, 590, 223, 
25002, 40039, 59009, 59320, 75310-1, 
75319 
Atrial fibrillation Defined from diagnosis codes ICD-10: I48 
Cancer 
Defined from all cancer 
diagnosis codes, excluding non-
melanoma skin cancer 
ICD-10: C00-C43, C45-C97 
ICD-8: 109-140 
Peripheral arterial 
disease 
Defined from diagnosis codes 
ICD-10: I709 
ICD-8: 440 
Chronic obstructive 
pulmonary disease 
Defined from diagnosis codes 
ICD-10: J42-J44 
ICD-8: 491, 492 
Concomitant treatment 
Oral anticoagulants 
Warfarin and non-vitamin K 
antagonist oral anticoagulants 
ATC: BO1AA03, B01AE07 
Aspirin Acetylsalicylic acid ATC: BO1AC06 
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Non-steroidal anti-
inflammatory drugs 
 ATC: M01A 
Statins  ATC: C10A 
Beta-blockers  ATC: C07 
Renin angiotensin 
system inhibitors 
Including: angiotensin-
converting-enzyme inhibitors, 
angiotensin-II receptor blockers 
ATC: C09 
Loop-diuretics  ATC: C03C 
Oral glucose-
lowering drugs 
 ATC: A10 
   
CPAP=Continuous positive airway pressure 
ATC:                  Anatomical Therapeutic Chemical system 
ICD-8:                8th revision of the International Classification of Diseases system 
ICD-10:             10th revision of the International Classification of Diseases system 
Diagnoses (primary or secondary), surgical procedures, and pharmacotherapy used for defining the study population, 
comorbidity, concomitant treatment, and outcomes. 
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